Literature DB >> 26217455

Non-invasive diagnostic imaging of colorectal liver metastases.

Pier Paolo Mainenti1, Federica Romano1, Laura Pizzuti1, Sabrina Segreto1, Giovanni Storto1, Lorenzo Mannelli1, Massimo Imbriaco1, Luigi Camera1, Simone Maurea1.   

Abstract

Colorectal cancer is one of the few malignant tumors in which synchronous or metachronous liver metastases [colorectal liver metastases (CRLMs)] may be treated with surgery. It has been demonstrated that resection of CRLMs improves the long-term prognosis. On the other hand, patients with un-resectable CRLMs may benefit from chemotherapy alone or in addition to liver-directed therapies. The choice of the most appropriate therapeutic management of CRLMs depends mostly on the diagnostic imaging. Nowadays, multiple non-invasive imaging modalities are available and those have a pivotal role in the workup of patients with CRLMs. Although extensive research has been performed with regards to the diagnostic performance of ultrasonography, computed tomography, positron emission tomography and magnetic resonance for the detection of CRLMs, the optimal imaging strategies for staging and follow up are still to be established. This largely due to the progressive technological and pharmacological advances which are constantly improving the accuracy of each imaging modality. This review describes the non-invasive imaging approaches of CRLMs reporting the technical features, the clinical indications, the advantages and the potential limitations of each modality, as well as including some information on the development of new imaging modalities, the role of new contrast media and the feasibility of using parametric image analysis as diagnostic marker of presence of CRLMs.

Entities:  

Keywords:  Advances in imaging; Colorectal cancer; Liver metastases

Year:  2015        PMID: 26217455      PMCID: PMC4506934          DOI: 10.4329/wjr.v7.i7.157

Source DB:  PubMed          Journal:  World J Radiol        ISSN: 1949-8470


  114 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

Review 2.  Strategies for safer liver surgery and partial liver transplantation.

Authors:  Pierre-Alain Clavien; Henrik Petrowsky; Michelle L DeOliveira; Rolf Graf
Journal:  N Engl J Med       Date:  2007-04-12       Impact factor: 91.245

3.  Navigated three-dimensional T1-weighted gradient-echo sequence for gadoxetic acid liver magnetic resonance imaging in patients with limited breath-holding capacity.

Authors:  Jeong Hee Yoon; Jeong Min Lee; Eun Sun Lee; Jeehyun Baek; Sangwoo Lee; Yuji Iwadate; Joon Koo Han; Byung Ihn Choi
Journal:  Abdom Imaging       Date:  2015-02

Review 4.  Liver metastases: Contrast-enhanced ultrasound compared with computed tomography and magnetic resonance.

Authors:  Vito Cantisani; Hektor Grazhdani; Cristina Fioravanti; Maria Rosignuolo; Fabrizio Calliada; Daniela Messineo; Maria Giulia Bernieri; Adriano Redler; Carlo Catalano; Ferdinando D'Ambrosio
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

5.  Whole-liver CT texture analysis in colorectal cancer: Does the presence of liver metastases affect the texture of the remaining liver?

Authors:  Sheng-Xiang Rao; Doenja Mj Lambregts; Roald S Schnerr; Wenzel van Ommen; Thiemo Ja van Nijnatten; Milou H Martens; Luc A Heijnen; Walter H Backes; Cornelis Verhoef; Meng-Su Zeng; Geerard L Beets; Regina Gh Beets-Tan
Journal:  United European Gastroenterol J       Date:  2014-12       Impact factor: 4.623

6.  Liver resection for colorectal metastases.

Authors:  Y Fong; A M Cohen; J G Fortner; W E Enker; A D Turnbull; D G Coit; A M Marrero; M Prasad; L H Blumgart; M F Brennan
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

Review 7.  [18F]FDG-PET-CT for early monitoring of tumor response: when and why.

Authors:  G Storto; E Nicolai; M Salvatore
Journal:  Q J Nucl Med Mol Imaging       Date:  2009-04       Impact factor: 2.346

Review 8.  Vascular and biliary variants in the liver: implications for liver surgery.

Authors:  Onofrio A Catalano; Anandkumar H Singh; Raul N Uppot; Peter F Hahn; Cristina R Ferrone; Dushyant V Sahani
Journal:  Radiographics       Date:  2008 Mar-Apr       Impact factor: 5.333

9.  F-18 FDG PET/CT in the assessment of patients with unexplained CEA rise after surgical curative resection for colorectal cancer.

Authors:  S Giacomobono; R Gallicchio; D Capacchione; A Nardelli; D Gattozzi; G Lettini; L Molinari; P Mainenti; A Cammarota; G Storto
Journal:  Int J Colorectal Dis       Date:  2013-07-12       Impact factor: 2.571

10.  What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis : imaging for recurrent colorectal cancer.

Authors:  Monique Maas; Iris J G Rutten; Patty J Nelemans; Doenja M J Lambregts; Vincent C Cappendijk; Geerard L Beets; Regina G H Beets-Tan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-06       Impact factor: 9.236

View more
  9 in total

Review 1.  Surveillance after curative treatment for colorectal cancer.

Authors:  Eric P van der Stok; Manon C W Spaander; Dirk J Grünhagen; Cornelis Verhoef; Ernst J Kuipers
Journal:  Nat Rev Clin Oncol       Date:  2016-12-20       Impact factor: 66.675

Review 2.  Imaging of Colorectal Liver Metastasis.

Authors:  Azarakhsh Baghdadi; Sahar Mirpour; Maryam Ghadimi; Mina Motaghi; Bita Hazhirkarzar; Timothy M Pawlik; Ihab R Kamel
Journal:  J Gastrointest Surg       Date:  2021-10-18       Impact factor: 3.452

3.  Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer.

Authors:  Zhen Yuan; Shuyuan Wang; Kemin Ni; Yixiang Zhan; Hong Ma; Xinyu Liu; Ran Xin; Xingyu Zhou; Zhaoce Liu; Xuanzhu Zhao; Xin Yin; Hangyu Ping; Yaohong Liu; Wanting Wang; Suying Yan; Qiurong Han; Wei Cui; Xipeng Zhang; Qinghuai Zhang; Chunze Zhang
Journal:  Med Sci Monit       Date:  2022-09-19

Review 4.  Current state of the art imaging approaches for colorectal liver metastasis.

Authors:  Bita Hazhirkarzar; Pegah Khoshpouri; Mohammadreza Shaghaghi; Mounes Aliyari Ghasabeh; Timothy M Pawlik; Ihab R Kamel
Journal:  Hepatobiliary Surg Nutr       Date:  2020-02       Impact factor: 7.293

Review 5.  Role of ultrasound in colorectal diseases.

Authors:  Renáta Bor; Anna Fábián; Zoltán Szepes
Journal:  World J Gastroenterol       Date:  2016-11-21       Impact factor: 5.742

Review 6.  Colorectal cancer: Parametric evaluation of morphological, functional and molecular tomographic imaging.

Authors:  Pier Paolo Mainenti; Arnaldo Stanzione; Salvatore Guarino; Valeria Romeo; Lorenzo Ugga; Federica Romano; Giovanni Storto; Simone Maurea; Arturo Brunetti
Journal:  World J Gastroenterol       Date:  2019-09-21       Impact factor: 5.742

Review 7.  Clinical Utility of Positron Emission Tomography Magnetic Resonance Imaging (PET-MRI) in Gastrointestinal Cancers.

Authors:  Robert Matthews; Minsig Choi
Journal:  Diagnostics (Basel)       Date:  2016-09-09

8.  Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study.

Authors:  Julia Bergheim; Alexander Semaan; Heidrun Gevensleben; Susanne Groening; Andreas Knoblich; Jörn Dietrich; Julia Weber; Jörg C Kalff; Friedrich Bootz; Glen Kristiansen; Dimo Dietrich
Journal:  Br J Cancer       Date:  2018-04-03       Impact factor: 7.640

9.  Austrian consensus guidelines on imaging requirements prior to hepatic surgery and during follow-up in patients with malignant hepatic lesions.

Authors:  Dietmar Tamandl; Ahmed Ba-Ssalamah; Gernot Böhm; Klaus Emmanuel; Rosemarie Forstner; Reinhold Függer; Benjamin Henninger; Oliver Koch; Claus Kölblinger; Hans-Jörg Mischinger; Wolfgang Schima; Helmut Schöllnast; Stefan Stättner; Klaus Kaczirek
Journal:  Wien Klin Wochenschr       Date:  2018-08-30       Impact factor: 1.704

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.